Testosterone replacement therapy works through five fundamentally different delivery systems, each with distinct pharmacokinetics and practical trade-offs. Injections achieve the highest serum concentrations but create pronounced peaks and troughs. Gels mimic natural diurnal patterns but require daily application and carry transfer risks. Pellets offer months-long stability with surgical implantation. Oral formulations provide convenience at the cost of hepatic first-pass metabolism. Nasal gels preserve pulsatile release but demand multiple daily doses.
The right method depends on your testosterone levels, symptom profile, lifestyle constraints, and tolerance for needles or procedures. A 42-year-old with total testosterone at 280 ng/dL faces different practical considerations than a 55-year-old at 190 ng/dL who travels frequently for work.
This comparison synthesizes clinical pharmacokinetic data, adherence patterns from recent trials, cost structures, and real-world implementation challenges. You'll see how each method achieves therapeutic levels, what monitoring demands look like, and which practical factors most often drive method switches.
Related Treatment Information
Injectable options: Testosterone cypionate offers the most established protocol with extensive generic availability. Testosterone undecanoate provides superior stability for patients prioritizing adherence.
Transdermal formulations: AndroGel and Testim lead gel market share. Generic alternatives provide cost savings with identical bioavailability profiles.
Pellet therapy: Testopel remains the primary FDA-approved pellet formulation. Cash-pay clinics dominate this space due to limited insurance coverage.
Decision tools: Use the TRT Method Selector Tool to input your specific parameters. The Comparison Calculator estimates out-of-pocket costs based on your insurance structure.
Next steps: Schedule a consultation to review lab values and lifestyle factors. Most providers recommend starting with the least invasive effective option, then adjusting based on 3-month outcomes.
Injectable Testosterone: Pharmacokinetics and Protocols
Intramuscular testosterone exists in short-acting and long-acting formulations with dramatically different serum patterns. Testosterone cypionate (TC) and enanthate reach peak serum levels 24-48 hours post-injection, then decline with an 8-day half-life. Weekly 100-200 mg dosing creates supraphysiologic peaks above 1,000 ng/dL and subphysiologic troughs below 300 ng/dL by day 7.1
Testosterone undecanoate (TU) changes that pattern entirely. The 750 mg injection has a 34-day half-life and delivers stable serum levels between 500-800 ng/dL without pronounced fluctuations.1 Loading doses at baseline and week 6 establish steady state, then maintenance injections every 10 weeks sustain therapeutic levels.
These pharmacokinetic differences translate to adherence outcomes. In treatment-naive patients, TU achieved 82% adherence versus 40.8% for TC during months 7-12, with 41.9% of TU patients remaining on therapy at 12 months compared to 8.2% for TC.1 The stability and reduced injection frequency matter more than initial convenience concerns.
Subcutaneous Administration
Subcutaneous injection of TC or enanthate uses smaller needles (27-30 gauge, 0.5 inch) and lower volumes (0.2-0.5 mL) compared to intramuscular delivery. More frequent dosing — every 3.5 days or twice weekly — reduces peak-to-trough variation while maintaining the same total weekly dose. Absorption from subcutaneous fat is slower and more consistent than deep muscle injection.
Pharmacokinetics describes how the body absorbs, distributes, metabolizes, and eliminates a drug over time, determining serum levels and duration of action.
Transdermal Gels: Absorption Patterns and Application
Testosterone gels absorb through intact skin at approximately 10% bioavailability with a 10-hour half-life.2 Daily morning application produces a diurnal pattern closer to endogenous testosterone production than injectable methods, reaching steady state within 24-48 hours.
Standard dosing starts at 50 mg daily (AndroGel 1.62% delivers 40.5 mg per pump) and titrates in 25 mg increments every 4-6 weeks based on morning total testosterone levels. Therapeutic range targets 400-700 ng/dL, achieved in most patients at 50-100 mg daily doses.2
But bioavailability varies with application site, skin thickness, and dermal blood flow. Shoulders and upper arms absorb more consistently than abdomen or thighs. Occlusive clothing or activity-induced sweating within 2-6 hours of application reduces absorption unpredictably.
Transfer Risk and Mitigation
Skin-to-skin contact transfers testosterone to partners and children before gel dries completely. Documented cases include virilization in female partners and precocious puberty in children exposed through casual contact.3 Covering application sites with clothing, waiting 2-4 hours before contact, or showering 6 hours post-application reduces but doesn't eliminate transfer risk.
Bioavailability is the percentage of an administered dose that reaches systemic circulation in an active form, affecting how much testosterone is available for therapeutic effect.
Subcutaneous Pellets: Zero-Order Release Kinetics
Testopel pellets (75 mg each) are implanted subcutaneously in the hip or buttock under local anesthesia. Typical protocols use 6-12 pellets (450-900 mg total) every 3-6 months depending on individual metabolism and target levels. The pellets release testosterone through constant zero-order kinetics, producing stable serum concentrations between 500-800 ng/dL without the peaks and troughs of injections.
This stability comes at the cost of inflexibility. Once implanted, pellets cannot be removed easily if adverse effects develop or levels run too high. Extrusion rates — pellets working their way out through the skin — occur in 1-3% of patients. Infection at the implantation site is rare but requires pellet removal and antibiotic therapy.
The implantation procedure takes 15-20 minutes. A small incision allows insertion of multiple pellets through a trocar, then closure with surgical adhesive or a single suture. Patients avoid strenuous lower body exercise for 3-5 days to prevent displacement.
Zero-Order Kinetics describes constant drug release at a fixed rate per unit time, independent of concentration, producing stable serum levels without fluctuations.
Oral and Nasal Formulations: Non-Injectable Alternatives
Oral testosterone undecanoate (Jatenzo) requires twice-daily dosing with meals for lymphatic absorption, bypassing hepatic first-pass metabolism that made older oral formulations hepatotoxic. Starting doses of 237 mg twice daily titrate to 396 mg based on serum levels drawn 4-6 hours post-dose. Bioavailability reaches 7-10% with adequate fat intake but drops significantly if taken without food.
The short 3-5 hour half-life creates variable serum patterns throughout the day. Missed doses produce rapid declines below therapeutic range. This pharmacokinetic profile makes oral undecanoate the least stable delivery method but appealing for needle-averse patients willing to maintain strict dosing schedules.
Nasal testosterone gel (Natesto) delivers 5.5 mg per nostril three times daily, producing pulsatile serum patterns that more closely mimic endogenous production than other methods.4 The rapid absorption and clearance result in testosterone pulses every 6-8 hours rather than sustained elevation, which may reduce side effects like erythrocytosis that correlate with sustained supraphysiologic levels.
First-Pass Metabolism is hepatic inactivation of orally ingested drugs before they enter systemic circulation, reducing bioavailability unless bypass routes like lymphatic absorption are used.
Method Comparison: Pharmacokinetics and Outcomes
Clinical trials comparing TRT methods show meaningful differences in adherence, stability, and patient satisfaction beyond simple testosterone delivery. This data shapes method selection for specific patient profiles and practical constraints.
| Method | Half-Life | Time to Steady State | Typical Serum Range | 12-Month Adherence |
|---|---|---|---|---|
| TC Injection (weekly) | 8 days | 4-6 weeks | Peak >1,000 ng/dL, trough <300 ng/dL | 40.8% months 7-121 |
| TU Injection (10-week) | 34 days | 10 weeks | Stable 500-800 ng/dL | 82% months 7-121 |
| Gel (daily) | 10 hours | 24-48 hours | Stable 400-700 ng/dL | Lower than injections (specific data unavailable) |
| Pellets (3-6 months) | ~90 days | 4-8 weeks | Stable 500-800 ng/dL | High satisfaction but limited trial data |
| Oral undecanoate (BID) | 3-5 hours | 24-48 hours | Variable 300-600 ng/dL | Poor due to dosing frequency |
Symptom Improvement Timeline
All methods improve hypogonadal symptoms, but timelines differ by stability of serum levels. Patients on gels or stable injection protocols report libido improvements within 4-12 weeks, with erectile function gains measured by IIEF-EF scores showing small but consistent effect sizes (SMD 0.16).3 Energy and mood changes typically precede sexual function improvements by 2-4 weeks.
| Method | Monthly Cost (Generic) | Monthly Cost (Brand) | Insurance Coverage |
|---|---|---|---|
| TC injection | $20-50 per vial (4-8 weeks) | N/A (generic standard) | Usually covered with prior authorization |
| TU injection (Aveed) | N/A | $1,000-2,000 per dose (every 10 weeks) | Variable, often requires step therapy |
| Gel | $20-200 | $300-600 | Common but may require TC trial first |
| Pellets | N/A | $500-1,000 per procedure (every 3-6 months) | Rarely covered, usually cash pay |
| Oral undecanoate | Emerging | $200-400 | Limited, prior authorization required |
Generic testosterone cypionate remains the most cost-effective option at $5-15 per month for most protocols. Insurance coverage heavily favors injectable TC as first-line therapy, with gels requiring documentation of injection intolerance or contraindication in many plans.
Practical Implementation: What to Expect
Starting TRT with injections requires comfort with self-administration or regular clinic visits. Most patients learn intramuscular injection technique within 2-3 sessions using ventrogluteal or vastus lateralis sites. Subcutaneous administration in abdominal fat is simpler and less intimidating for needle-averse patients.
You'll draw back slightly before injecting to confirm you're not in a vessel, then inject slowly over 30-60 seconds. Post-injection soreness peaks 24-48 hours later and diminishes with regular use as tissue adapts.
Gel Application Protocol
Apply gel to clean, dry skin immediately after showering. Shoulders and upper arms work best — avoid areas covered by clothing during absorption time. Spread the gel thinly over the recommended surface area (about the size of both palms). Let it dry 3-5 minutes before dressing.
Set an alarm for 6 hours post-application as a reminder that transfer risk drops significantly after showering. If you exercise within 2 hours of application, consider switching to evening dosing or using a different delivery method.
Pellet Procedure Experience
Arrive at the clinic with loose-fitting pants. The procedure happens in the office under local anesthesia. You'll feel pressure during insertion but minimal pain. The incision site stays covered with a waterproof dressing for 3-5 days.
Avoid heavy squats, deadlifts, or aggressive hip movements for one week. Most patients return to full activity within 7-10 days. The implant site may feel firm or lumpy for 2-3 weeks as tissue encapsulates the pellets.
Timeline Expectations
Libido improvements start 3-6 weeks into treatment regardless of method, assuming serum levels reach therapeutic range. Energy and mood stabilize around the same timeframe. Physical changes like fat-free mass gains require 3-6 months of sustained levels above 400 ng/dL.3
Erectile function changes lag behind other symptoms. If you don't see improvement by 12 weeks, address vascular or psychological factors that testosterone alone won't fix.
Safety Profiles and Monitoring Requirements
All testosterone delivery methods carry similar systemic risks because they achieve comparable serum concentrations. The differences lie in method-specific side effects and monitoring complexity.
| Method | Unique Side Effects | Monitoring Labs | Lab Timing |
|---|---|---|---|
| TC/TU injection | Injection site pain, oil-based granuloma (rare), mood swings with TC peaks/troughs | Total T, hematocrit, PSA, lipids | Trough level (day before next injection) at 6 weeks, then every 6 months |
| Gel | Skin irritation, transfer to contacts, inconsistent absorption | Total T, hematocrit, PSA, lipids | Morning level 2-4 hours post-application at 4 weeks, then every 6 months |
| Pellets | Extrusion (1-3%), infection, difficulty adjusting dose | Total T, hematocrit, PSA, lipids | Mid-cycle (6-8 weeks post-insertion), then every 3-6 months |
| Oral | GI upset, variable absorption with food timing | Total T, liver function, hematocrit, PSA, lipids | 4-6 hours post-dose at 4 weeks, then every 3-6 months with liver monitoring |
Erythrocytosis Management
Elevated hematocrit above 54% occurs in 15-20% of TRT patients regardless of method, though sustained supraphysiologic levels from weekly TC increase risk. Therapeutic phlebotomy (donating 1 unit of blood) typically resolves the issue, but recurring elevations may require dose reduction or switching to methods with lower peak levels.
Cardiovascular Monitoring
Recent meta-analyses show no significant cardiovascular risk increase with physiologic testosterone replacement, but patients with pre-existing coronary disease require closer monitoring.3 Blood pressure checks at every visit and lipid panels every 6 months identify emerging issues before they become clinically significant.
Atrial fibrillation has inconsistent associations with TRT in observational data. If you have existing arrhythmia, starting with lower doses and monitoring for symptom changes provides an appropriate safety margin.